KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short term Debt: 2023-2024

Historic Short term Debt for Rigel Pharmaceuticals (RIGL) over the last 2 years, with Dec 2024 value amounting to $7.3 million.

  • Rigel Pharmaceuticals' Short term Debt was N/A to $29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year change of. This contributed to the annual value of $7.3 million for FY2024, which is 0.59% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Short term Debt stood at $7.3 million for FY2024, which was up 0.59% from $7.2 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Short term Debt registered a high of $7.3 million during FY2024, and its lowest value of $7.2 million during FY2023.
  • Its 2-year average for Short term Debt is $7.3 million, with a median of $7.3 million in 2023.
  • Data for Rigel Pharmaceuticals' Short term Debt shows a peak YoY climbed of 0.59% (in 2024) over the last 5 years.
  • Rigel Pharmaceuticals' Short term Debt (Yearly) stood at $7.2 million in 2023, then grew by 0.59% to $7.3 million in 2024.